A “Jacob Moses MD Memorial Lecture” offers a new perspective on Blue light and innovative technology to prevent disease while enhancing visual performance.

Melanin and Ocular Lens Pigment are natural defenses to filter Blue light in skin and eyes. Innovative external lenses using these derivatized compounds complement the human body to reduce glare, improve sleep, balance circadian rhythm to maintain overall health, and may prevent blindness.

Dr. Michael Tolentino MD delivered the prestigious “Jacob Moses MD Memorial Lectureship” to an audience of over 40 eye doctors in Columbus Ohio regarding the impact of naturally occurring and artificially generated sources of High Energy Visible (Blue) light on the primary optical tract and retinal-hypothalamic tract. “Blue light threatens our eyes, our vision, and circadian rhythm,” explained Dr. Tolentino. He detailed preventative measures to protect our visual and physiological systems using cost-effective external lenses to enhance natural defenses.

The human body produces Melanin and Ocular Lens Pigment, which were paradigms for Blue light protection, and patented by Dr. James Gallas of Photoprotective Technologies as derivatives that filter light in proportion to the Blue light wavelengths ability to cause damage.

“The combination of Melanin and Ocular Lens Pigment (OLPTM) provide more effective filtration of Blue light than anything I am aware of and I recommend using the lenses to reduce issues involving glare and damage to the retina and macula from prolonged or intense Blue light exposure. Further, the MPF lens promotes balanced Melatonin production, critical to proper physiological function to help mitigate chronic diseases including cardiovascular issues, depression, diabetes, obesity, and cancer,” explained Dr. Tolentino.

About Dr. Michael Tolentino: He is Associate Professor of Clinical Ophthalmology at the University of Central Florida and co-founder of the Tolentino Eye Research Foundation (www.tolentinoeye.org) is recognized globally as a medical authority, whose qualifications include education or faculty at Brown University, Harvard University, University of Massachusetts and University of Pennsylvania. He co- invented the concept of intravitreal anti-Vascular Endothelial Growth Factor (VEGF) injections, in particular, the drug Avastin. He is credited for determining that VEGF is sufficient and necessary for the development of diseases such as diabetic retinopathy and wet macular degeneration. He also co-invented Bevasiranib a siRNA against VEGF. As a clinical trialist, he has helped more than half a dozen drugs or treatments for the eye obtain FDA approval.? He is currently developing novel topical, nutritional, and preventative alternatives to prevent blindness.

TrueBlue Vision holds the exclusive production of lenses and products for both natural (outdoor) and artificial (indoor) blue light filtration. After an extensive review of product performance, TrueBlue was recently chosen by “IRIS The Visual Group” Canada’s largest network of Eyecare Professionals. To learn more about preventative strategies and novel therapies for retinal diseases such as macular degeneration and diabetic retinopathy, please visit http://www.tolentinoeye.org.? To learn more about the Blue Light Threat and TrueBlue lenses, please visit http://www.truebluevision.com

Source: TrueBlue Vision,?Displayed with permission from PRNewswire for Journalists

Got Questions? We have Answers! Contact us at CriteriumBlog@criteriuminc.com